Literature DB >> 6173360

Monoclonal and xenoantibodies specific for HLA-DR inhibit primary responses to HLA-D but fail to inhibit secondary proliferative (PLT) responses to allogeneic cells.

D D Eckels, J N Woody, R J Hartzman.   

Abstract

Monoclonal antibodies (DA-2 and CA-2) and xenoantisera (rabbit anti-human, p23,30) specific for HLA-DR framework determinants were added to primary and secondary mixed lymphocyte cultures. Although such antisera were shown to inhibit primary MLC, primed lymphocytes were much less sensitive to the blocking effects of these antibodies. In the studies shown here, the concentration of antibody required to inhibit primary MLC reactions was 0.1-1.5 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6173360     DOI: 10.1016/0198-8859(81)90050-1

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  5 in total

1.  Induction of lymphocyte proliferation by antigen-pulsed human neutrophils.

Authors:  C Prior; P J Townsend; D A Hughes; P L Haslam
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

Review 2.  Analysis of antigen presentation using HLA transfectants.

Authors:  D M Altmann; D Wilkinson; H Ikeda; J Trowsdale
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

3.  Characterization of human T-lymphocyte clones (TLCs) specific for HLA-region gene products.

Authors:  D D Eckels; R J Hartzman
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

4.  Unusual distribution of Ia-like antigens on canine lymphocytes.

Authors:  H J Deeg; J C Wulff; S DeRose; G E Sale; M Braun; M A Brown; S C Springmeyer; P J Martin; R Storb
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

5.  Enhancement of the antigen-presenting function of monocytes by cholesterol: possible relevance to inflammatory mechanisms in extrinsic allergic alveolitis and atherosclerosis.

Authors:  D A Hughes; P J Townsend; P L Haslam
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.